West Pharmaceutical Services, Inc. (WST) Stock Forecast
WST analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.65 / 5 from 17 analysts
- Price target
- $412.88 average of analyst targets
- Upside to target
- +7.5% from the latest close
- Next earnings
- October 29, 2026 EPS estimate $2.18
- 52-week range
- $230.95 – $384.02
WST analyst ratings
17 analystsNumber of analysts at each rating.
WST price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
WST earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.20 | $2.16 | $2.23 | $1.96 | +12.1% | 15 |
| Current fiscal year (2026) | $8.96 | $8.83 | $9.05 | $7.29 | +22.9% | 17 |
| Next fiscal year (2027) | $10.00 | $9.71 | $10.67 | $8.96 | +11.6% | 17 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
WST revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $826.5M | $821.0M | $836.0M | +2.7% | 12 |
| Current fiscal year (2026) | $3.38B | $3.36B | $3.40B | +9.8% | 16 |
| Next fiscal year (2027) | $3.59B | $3.50B | $3.68B | +6.3% | 16 |
WST EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
WST revenue: reported and forecast
WST EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.13 | $2.19 | $2.19 | $2.20 | $2.20 | +3.4% | 1 up · 0 down |
| Current fiscal year (2026) | $8.62 | $8.96 | $8.96 | $8.96 | $8.96 | +4.0% | 1 up · 0 down |
| Next fiscal year (2027) | $9.62 | $9.96 | $9.98 | $9.99 | $10.00 | +3.9% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
WST earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; WST beat in 11 of 12.
What analysts expect from WST
17 analysts cover West Pharmaceutical; their consensus rating is strong buy (4.65 on a 1–5 scale, where 5 is a strong buy). The average price target is $412.88, 7.5% above the latest close of $384.02. Analysts expect earnings of $8.96 per share for 2026, +22.9% from a year earlier. For 2027 the average estimate is $10.00 per share on revenue of $3.6 billion. West Pharmaceutical beat the EPS estimate in 11 of the last 12 quarters.
Related: WST income statement, WST key metrics, WST chart. See the WST stock overview for the latest quote and news.
WST forecast FAQ
What is West Pharmaceutical's price target?
The average analyst price target for West Pharmaceutical is $412.88, 7.5% above the latest close of $384.02.
Is West Pharmaceutical a buy, hold or sell?
Of 17 analysts covering West Pharmaceutical, 12 rate it a strong buy, 4 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is West Pharmaceutical's EPS forecast?
Analysts forecast $8.96 per share for 2026 (range $8.83 to $9.05); for 2027 the estimate is $10.00.
What is West Pharmaceutical's revenue forecast?
The average revenue estimate for 2026 is $3.4 billion, growth of 9.8%; for 2027 it is $3.6 billion.
When does West Pharmaceutical report earnings?
West Pharmaceutical is expected to report results for the quarter ending September 30, 2026 on October 29, 2026 before the market opens; the EPS estimate is $2.18.
Does West Pharmaceutical usually beat earnings estimates?
West Pharmaceutical reported EPS at or above the analyst estimate in 11 of the last 12 quarters.